Immuron Ltd (ASX: IMC) Share Price and News
Price
Movement
52 Week Range
-
1 Year Return
(20 mins delayed)
() Chart and Price Data
Share Price
Previous Close
Volume
Day Change
Open
Monthly Average Volume
52 Week Range
-
Days Range
-
Turnover
Fundamental Company Figures
Data provided by Morningstar.
Market Cap
$43.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Shares Outstanding
224.10 million
Earnings per share
-0.034
Dividend per share
N/A
Year To Date Return
-17.39%
Earnings Yield
N/A
Franking
N/A
Immuron Limited (ASX: IMC) Latest News
Why the Immuron (ASX:IMC) share price is rocketing up 10% today
Aaron Teboneras | December 15, 2020 3:07pm
Why the Immuron (ASX:IMC) share price is rocketing 18% higher today
Bernd Struben | November 9, 2020 2:47pm
Afterpay and Immuron were among the most traded shares on the ASX last week
James Mickleboro | July 28, 2020 3:21pm
Immuron share price falls 27% on registered direct offering
Daniel Ewing | July 22, 2020 11:21am
Immuron share price shoots 90% higher on potential COVID-19 treatment news
Daniel Ewing | July 21, 2020 11:35am
Immuron share price shoots 6% higher after receiving FDA guidance for new drug
Daniel Ewing | July 20, 2020 4:28pm
Recent Stock Announcements
Price Sensitive OnlyAn announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Show All
| Date | Heading | An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. | Time | Pages | File Size |
|---|---|---|---|---|---|
About Immuron Ltd (ASX: IMC)
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Share Price History
Data provided by Morningstar.| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 16 Apr 2021 | $0.19 | $0.00 | 0.00% | 174,771 | $0.19 | $0.19 | $0.19 |
| 15 Apr 2021 | $0.19 | $0.00 | 0.00% | 183,823 | $0.19 | $0.20 | $0.19 |
| 14 Apr 2021 | $0.19 | $-0.01 | -5.00% | 221,692 | $0.19 | $0.20 | $0.19 |
| 13 Apr 2021 | $0.20 | $0.00 | 0.00% | 378,073 | $0.19 | $0.20 | $0.19 |
| 12 Apr 2021 | $0.20 | $0.00 | 0.00% | 230,597 | $0.20 | $0.20 | $0.20 |
| 09 Apr 2021 | $0.20 | $0.01 | 5.13% | 130,587 | $0.20 | $0.20 | $0.20 |
| 08 Apr 2021 | $0.20 | $-0.01 | -5.00% | 98,813 | $0.20 | $0.20 | $0.20 |
| 07 Apr 2021 | $0.20 | $0.00 | 0.00% | 490,864 | $0.21 | $0.21 | $0.20 |
| 06 Apr 2021 | $0.21 | $0.00 | 0.00% | 139,323 | $0.21 | $0.21 | $0.21 |
| 01 Apr 2021 | $0.21 | $0.00 | 0.00% | 67,200 | $0.20 | $0.21 | $0.20 |
| 31 Mar 2021 | $0.20 | $0.00 | 0.00% | 37,339 | $0.20 | $0.21 | $0.20 |
| 30 Mar 2021 | $0.20 | $0.00 | 0.00% | 121,077 | $0.20 | $0.20 | $0.20 |
| 29 Mar 2021 | $0.20 | $0.00 | 0.00% | 174,488 | $0.20 | $0.21 | $0.20 |
| 26 Mar 2021 | $0.20 | $0.00 | 0.00% | 153,723 | $0.20 | $0.21 | $0.20 |
| 25 Mar 2021 | $0.20 | $0.00 | 0.00% | 419,796 | $0.21 | $0.21 | $0.20 |
| 24 Mar 2021 | $0.21 | $0.00 | 0.00% | 330,466 | $0.21 | $0.22 | $0.21 |
| 23 Mar 2021 | $0.21 | $0.00 | 0.00% | 17,317 | $0.21 | $0.21 | $0.21 |
| 22 Mar 2021 | $0.21 | $0.00 | 0.00% | 4,007 | $0.21 | $0.21 | $0.21 |
| 19 Mar 2021 | $0.21 | $-0.01 | -4.76% | 214,780 | $0.21 | $0.21 | $0.21 |
| 18 Mar 2021 | $0.21 | $-0.01 | -4.65% | 99,428 | $0.21 | $0.22 | $0.21 |
| 17 Mar 2021 | $0.22 | $0.00 | 0.00% | 595 | $0.22 | $0.22 | $0.22 |
Director Transactions
Data provided by Morningstar.
Show more
Directors & Management
Data provided by Morningstar.
Show more
Top Share Holders
Data provided by Morningstar.| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 104,631,009 | 46.57% |
| Grandlodge Pty Ltd And Its Related Holdings | 11,778,269 | 5.26% |
| Authentics Australia Pty Ltd <Authentics Australia A/C> | 7,500,000 | 3.35% |
| Dr Russell Kay Hancock | 3,000,000 | 1.34% |
| Mr Stephen Anastasiou & Mrs Andria Anastasiou <Anastasiou Family S/F A/C> | 2,494,746 | 1.11% |
| Insync Investments Pty Ltd <Weekley Super Fund No 1 A/C> | 2,000,000 | 0.89% |
| Citicorp Nominees Pty Limited | 1,719,277 | 0.77% |
| Mr Anthony Frederick Wallace Hyett | 1,350,000 | 0.60% |
| Anne Pattison Pty Ltd <Aep No 3 A/C> | 1,345,000 | 0.60% |
| Mr William David Frank Bird | 1,300,000 | 0.58% |
| Inverarey Pty Ltd <The Kilchurn A/C> | 1,050,000 | 0.47% |
| Texas Woods Pty Ltd <The Plush Family A/C> | 978,393 | 0.44% |
| Mr Nick Karopoulos | 950,000 | 0.42% |
| Hadasit Medical Research Services & Development Ltd | 887,462 | 0.40% |
| Peppertree Custodian Services Pty Ltd <Mulcahy Superannuation A/C> | 860,634 | 0.38% |
| South Bay Nominees Pty Ltd <C & P Hong Family A/C> | 850,000 | 0.38% |
| Mr David Anthony Plush & Mrs Ann Louise Plush <Plush Super Fund A/C> | 834,075 | 0.37% |
| Mrs Rochelle Jane Pattison & Ms Katherine Margaret Forrest <Sylvan S/F A/C> | 800,000 | 0.36% |
| Advance Publicity Pty Ltd <The Izmar Family A/C> | 750,000 | 0.33% |